DoD Breast Cancer, Breakthrough Award Level 3 | W81XWH 22 BCRP BTA3

Opportunity Information: Apply for W81XWH 22 BCRP BTA3

The DoD Breast Cancer Research Program (BCRP) Breakthrough Award Level 3 (Funding Opportunity Number W81XWH-22-BCRP-BTA3) is a competitive Department of Defense grant/cooperative agreement mechanism run through the U.S. Army Medical Research Acquisition Activity (USAMRAA). Its purpose is to push forward breast cancer research that is genuinely positioned to change the field, not just add another incremental finding. Proposals are expected to make a clear case that the work could lead to a major shift in how breast cancer is prevented, detected, or treated, with the potential to accelerate progress toward ending breast cancer. A key requirement baked into the program’s intent is that applicants spell out who the work is for: the specific breast cancer patient populations or at-risk groups that would ultimately benefit if the project succeeds.

What sets the Breakthrough Award concept apart is its emphasis on impact that goes beyond a “minor advancement.” The program is looking for research that could plausibly deliver a new approach that is fundamentally better than what is already approved or already moving through clinical development. That impact can be near-term or longer-term, but it has to be credible and meaningful rather than speculative. This framing pushes applicants to connect strong science with a realistic pathway to translation, rather than stopping at basic discovery.

This announcement specifically covers Funding Level 3, which is defined as advanced translational research with a high degree of readiness to move toward the clinic. In practical terms, Level 3 projects should look like they are past early feasibility and are now prepared to validate, de-risk, and advance an intervention, diagnostic, or strategy toward human use. The opportunity explicitly expects proof, where relevant, that the team already has access to what is needed to execute: datasets, human biospecimens, patient cohorts, and other critical reagents. If the direction of travel would require FDA involvement, the application is expected to show that clinical-grade or otherwise appropriate reagents (for example, a therapeutic molecule) and a feasible patient population are available and accessible. Applicants also need to lay out a realistic timeline that points toward near-term clinical investigation, and the program notes that small-scale clinical trials, including first-in-human or phase 1/1b studies, may fit Level 3 when appropriate.

The Breakthrough Award is organized into four funding levels, each aligned to a different stage on the path to clinical application. A central rule in this structure is that investigators must choose the funding level based on the scope definition, not based on how large a budget they want. The announcement is clear that an otherwise strong proposal can be declined if it does not match the intent of Level 3, even if it might have fit Levels 1, 2, or 4. Those other levels are covered under separate announcements (W81XWH-22-BCRP-BTA12 for Levels 1 and 2, and W81XWH-22-BCRP-BTA4 for Level 4), and applicants are strongly encouraged to review them before submitting to make sure they are in the right lane.

Collaboration is encouraged through an optional Partnering PI structure that allows two principal investigators to apply as an integrated team. One PI serves as the Initiating PI and handles most submission and administrative responsibilities, while the other is the Partnering PI. The program is explicit that this is meant to support real co-leadership: both PIs should have substantial intellectual input into the project’s design and should contribute meaningfully across core application components such as the project narrative and statement of work. Effort levels are expected to be similar and appropriate, and the funding split is expected to be balanced unless there is a clear justification otherwise. The announcement also draws a bright line around what does not qualify as a true partnership: arrangements where one PI mostly provides materials (samples, animal models, investigational agents) while the other PI conducts most experiments and analysis are not considered consistent with the intent. It also discourages a single person from being listed as Partnering PI on multiple Level 3 applications unless the research questions are clearly distinct. If funded, each PI is expected to be associated with an individual award within the recipient organization.

Beyond the PI structure, the program expects a strong, well-matched research team with the breast cancer expertise needed to deliver on an advanced translational plan. Importantly, consumer advocate participation is not optional. Each application must include at least two breast cancer consumer advocates who are integrated into the project throughout planning and execution, not added as a token advisory role. Their expected involvement can include shaping the research question, informing design choices, helping oversee progress, contributing to recruitment considerations, and participating in evaluation of the work’s relevance and potential impact. These advocates must be breast cancer survivors, active in a breast cancer advocacy organization, and independent in the sense that they cannot be employees of any participating organization on the application. Their role is to provide objective, patient-centered input grounded in lived experience and informed understanding of current breast cancer issues, and the program expects them to have sufficient knowledge and/or training to contribute effectively.

Administratively, the opportunity is categorized as discretionary funding, with eligible applicants listed as unrestricted (open to entity types, subject to any additional eligibility notes in the full announcement). The activity category is science and technology and other research and development, under CFDA 12.420. The listing notes an expected number of awards of three. The original posting information shows a creation date of March 16, 2022 and an original closing date of July 27, 2022. The award ceiling is shown as 0 in the source data, which typically indicates that applicants must rely on the program announcement for the actual budget limits and constraints rather than interpreting the listing field as a meaningful cap.

Taken together, Breakthrough Award Level 3 is aimed at teams that are ready to move a high-impact breast cancer idea through late translational steps and into early clinical testing, with clear evidence that the needed resources, materials, and patient access are already lined up. The program strongly favors projects that can credibly change clinical direction or open a fundamentally better route than current options, while also requiring visible patient-centered grounding through substantial consumer advocate integration.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Breast Cancer, Breakthrough Award Level 3" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Mar 16, 2022.
• Applicants must submit their applications by Jul 27, 2022. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 3 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 22 BCRP BTA3

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: